132 related articles for article (PubMed ID: 32745802)
1. An immunological and transcriptomics approach on differential modulation of NK cells in multiple sclerosis patients under interferon-β1 and fingolimod therapy.
Acar NP; Tuncer A; Ozkazanc D; Ozbay FG; Karaosmanoglu B; Goksen S; Sayat G; Taskiran EZ; Esendagli G; Karabudak R
J Neuroimmunol; 2020 Oct; 347():577353. PubMed ID: 32745802
[TBL] [Abstract][Full Text] [Related]
2. Fingolimod Therapy in Multiple Sclerosis Leads to the Enrichment of a Subpopulation of Aged NK Cells.
Schwichtenberg SC; Wisgalla A; Schroeder-Castagno M; Alvarez-González C; Schlickeiser S; Siebert N; Bellmann-Strobl J; Wernecke KD; Paul F; Dörr J; Infante-Duarte C
Neurotherapeutics; 2021 Jul; 18(3):1783-1797. PubMed ID: 34244929
[TBL] [Abstract][Full Text] [Related]
3. Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta.
Saraste M; Irjala H; Airas L
Neurol Sci; 2007 Jun; 28(3):121-6. PubMed ID: 17603762
[TBL] [Abstract][Full Text] [Related]
4. CD3
Tahrali I; Kucuksezer UC; Akdeniz N; Altintas A; Uygunoglu U; Aktas-Cetin E; Deniz G
Immunol Lett; 2019 Dec; 216():63-69. PubMed ID: 31589897
[TBL] [Abstract][Full Text] [Related]
5. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
[TBL] [Abstract][Full Text] [Related]
6. Reduction of the peripheral blood CD56(bright) NK lymphocyte subset in FTY720-treated multiple sclerosis patients.
Johnson TA; Evans BL; Durafourt BA; Blain M; Lapierre Y; Bar-Or A; Antel JP
J Immunol; 2011 Jul; 187(1):570-9. PubMed ID: 21622858
[TBL] [Abstract][Full Text] [Related]
7. Treatment effects of fingolimod in multiple sclerosis: Selective changes in peripheral blood lymphocyte subsets.
Hjorth M; Dandu N; Mellergård J
PLoS One; 2020; 15(2):e0228380. PubMed ID: 32012202
[TBL] [Abstract][Full Text] [Related]
8. Impact of fingolimod on CD4+ T cell subset and cytokine profile of relapsing remitting multiple sclerosis patients.
Kürtüncü M; Yılmaz V; Akçay Hİ; Türkoğlu R; Altunrende B; Çınar SA; Ulusoy C; Gündüz T; İçöz S; Kasap M; Çalışkan Z; Ötünç G; Eraksoy M; Tüzün E
J Neuroimmunol; 2019 Dec; 337():577065. PubMed ID: 31526917
[TBL] [Abstract][Full Text] [Related]
9. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
Khatri B; Barkhof F; Comi G; Hartung HP; Kappos L; Montalban X; Pelletier J; Stites T; Wu S; Holdbrook F; Zhang-Auberson L; Francis G; Cohen JA;
Lancet Neurol; 2011 Jun; 10(6):520-9. PubMed ID: 21571593
[TBL] [Abstract][Full Text] [Related]
10. Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis.
Chitnis T; Arnold DL; Banwell B; Brück W; Ghezzi A; Giovannoni G; Greenberg B; Krupp L; Rostásy K; Tardieu M; Waubant E; Wolinsky JS; Bar-Or A; Stites T; Chen Y; Putzki N; Merschhemke M; Gärtner J;
N Engl J Med; 2018 Sep; 379(11):1017-1027. PubMed ID: 30207920
[TBL] [Abstract][Full Text] [Related]
11. Identification of a gene expression signature in peripheral blood of multiple sclerosis patients treated with disease-modifying therapies.
Cordiglieri C; Baggi F; Bernasconi P; Kapetis D; Faggiani E; Consonni A; Andreetta F; Frangiamore R; Confalonieri P; Antozzi C; Mantegazza R
Clin Immunol; 2016 Dec; 173():133-146. PubMed ID: 27720845
[TBL] [Abstract][Full Text] [Related]
12. Characterization of CD4+ and CD8+ T Cell Subsets and Interferon Regulatory Factor 4 (IRF4) in MS Patients Treated with Fingolimod (FTY-720): A Follow-up Study.
Laribi B; Sahraian MA; Shekarabi M; Emamnejad R; Marzban M; Sadaghiani S; Izad M
Iran J Allergy Asthma Immunol; 2018 Aug; 17(4):346-360. PubMed ID: 30537798
[TBL] [Abstract][Full Text] [Related]
13. Impact of interferon β-1b, interferon β-1a and fingolimod therapies on serum interleukins-22, 32α and 34 concentrations in patients with relapsing-remitting multiple sclerosis.
Abdel-Dayem MA; Shaker ME; Gameil NM
J Neuroimmunol; 2019 Dec; 337():577062. PubMed ID: 31521828
[TBL] [Abstract][Full Text] [Related]
14. Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS.
Meng X; Chin PS; Hashmonay R; Zahur Islam M; Cutter G
Contemp Clin Trials; 2015 Mar; 41():69-74. PubMed ID: 25545026
[TBL] [Abstract][Full Text] [Related]
15. Tissue Distribution Dynamics of Human NK Cells Inferred from Peripheral Blood Depletion Kinetics after Sphingosine-1-Phosphate Receptor Blockade.
Mehling M; Burgener AV; Brinkmann V; Bantug GR; Dimeloe S; Hoenger G; Kappos L; Hess C
Scand J Immunol; 2015 Nov; 82(5):460-6. PubMed ID: 26285786
[TBL] [Abstract][Full Text] [Related]
16. Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis.
Kalincik T; Jokubaitis V; Spelman T; Horakova D; Havrdova E; Trojano M; Lechner-Scott J; Lugaresi A; Prat A; Girard M; Duquette P; Grammond P; Solaro C; Grand'Maison F; Hupperts R; Prevost J; Sola P; Ferraro D; Terzi M; Butler E; Slee M; Kermode A; Fabis-Pedrini M; McCombe P; Barnett M; Shaw C; Hodgkinson S; Butzkueven H;
Mult Scler; 2018 Oct; 24(12):1617-1626. PubMed ID: 28857680
[TBL] [Abstract][Full Text] [Related]
17. Killer-cell immunoglobulin-like receptor expression on lymphocyte subsets in multiple sclerosis patients treated with interferon-β: evaluation as biomarkers for clinical response.
García-León JA; López-Gómez C; Orpez-Zafra T; Reyes-Garrido V; Marín-Bañasco C; Oliver-Martos B; Fernández O; Leyva L
CNS Drugs; 2014 Jun; 28(6):559-70. PubMed ID: 24599774
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study).
Comi G; Patti F; Rocca MA; Mattioli FC; Amato MP; Gallo P; Centonze D; Pozzilli C; Saccà F; Bergh FT; Bartezaghi M; Turrini R; Filippi M;
J Neurol; 2017 Dec; 264(12):2436-2449. PubMed ID: 29063244
[TBL] [Abstract][Full Text] [Related]
19. Altered T cell phenotypes associated with clinical relapse of multiple sclerosis patients receiving fingolimod therapy.
Fujii C; Kondo T; Ochi H; Okada Y; Hashi Y; Adachi T; Shin-Ya M; Matsumoto S; Takahashi R; Nakagawa M; Mizuno T
Sci Rep; 2016 Oct; 6():35314. PubMed ID: 27752051
[TBL] [Abstract][Full Text] [Related]
20. Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.
Lorscheider J; Benkert P; Lienert C; Hänni P; Derfuss T; Kuhle J; Kappos L; Yaldizli Ö
Mult Scler; 2018 May; 24(6):777-785. PubMed ID: 29685071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
